New issue · Fri 16 October

Audio Epilepsy Digest

On Air

In the current issue

Less invasive, but how much benefit?

Three recent studies ask what a smaller intervention can promise: treatment-specific benefit, durable seizure control, and a meaningful safety advantage.

In this episode: - A small sham-controlled taVNS crossover study and the difference between improvement and demonstrated superiority. - Long-term SEEG-guided radiofrequency thermocoagulation, changing treatment groups and incomplete follow-up. - Volume-based RF-TC for focal cortical dysplasia: a promising MRI safety signal with important limits.

Reading notes: - These interventions and populations are distinct, not a head-to-head comparison. - Hong’s pilot did not demonstrate active-treatment superiority to sham; it establishes neither equivalence nor universal ineffectiveness. - Pesente’s one-year 19/135 seizure-free result applies to the selected RF-TC-only group, including repeat procedures. The abstract mixes responder denominators; the disputed responder and five-year percentages are omitted from the episode. - Hayashi’s primary endpoint was MRI-detected deep white matter infarction. Overall neurological deficit rates were not significantly different. Similar observed seizure outcomes do not establish noninferiority or equivalence; favorable ILAE 1–3 is broader than seizure freedom.

In this issue3 topics

  1. What a sham-controlled taVNS pilot can and cannot establish about treatment-specific benefit.
  2. Long-term SEEG-guided RF-TC outcomes and the limits of selected cohorts and incomplete follow-up.
  3. Volume-based RF-TC for focal cortical dysplasia: distinguishing an MRI safety signal from overall neurological safety.

AED Quiz / AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

Back issues 22 issues

  1. No.22

    Monthly special

    The Epilepsy Follow-Up: Continue, Adjust, Switch—or Refer?

    An adult outpatient special prompted by a nurse practitioner's request: three everyday visits, from breakthrough seizures to treatment burden and repeated medication trials. The August 2025 Xcopri liver-label update provides a concrete example of checking medication-specific safety requirements.

    In this discussion · 4 topics

    1. Reassess breakthrough events, medication use and barriers before automatic escalation.
    2. Ask about treatment burden and daily function even when seizures have stopped.
    3. Review previous treatment adequacy and explain comprehensive epilepsy referral.
    4. Check medication-specific safety requirements, including the Xcopri liver-label update.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  2. No.21

    Monthly special

    FCD: What Does the Diagnosis Actually Tell Us?

    A monthly special on focal cortical dysplasia: what an integrated diagnosis explains, what anatomy and electrophysiology add, and where AI detection and targeted treatment remain uncertain.

    In this discussion · 3 topics

    1. Integrated diagnosis: imaging, pathology and molecular findings.
    2. Brain mosaicism and the limits of peripheral testing.
    3. Anatomy, AI detection and the limits of targeted treatment.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  3. No.20

    Weekly

    Who Decides on Epilepsy Surgery?

    From identifying people who have not reached evaluation to center-level recommendations and estimates of seizure benefit and visual harm, five papers examine how the path to epilepsy surgery is shaped—and what these studies cannot decide for an individual.

    In this discussion · 6 topics

    1. Caraway: recommendations varied across 29 pediatric centers after adjustment. A recommendation included invasive monitoring; it did not establish an operation, outcome, or inappropriate decision.
    2. Simmons: an EHR rule flagged possible cases for chart review. Among 84 confirmed cases of drug-resistant epilepsy, 48 had no evaluation initiated; the rule did not itself diagnose drug resistance.
    3. Coordinator tracking was associated with evaluation status. This observational finding establishes neither benefit nor lack of benefit from a coordinator intervention.
    4. Karpychev: MRI network measures showed an exploratory long-term outcome signal, with external AUC 0.65. The model is not a surgical exclusion rule or a resection map.
    5. Wreghitt: probabilistic tractography better delineated optic-radiation anatomy and estimated injury correlated with visual-field loss in 33 adults. It did not establish guaranteed safe margins or prevention of visual deficits.
    6. Englot supplies historical review-based referral context. Referral, recommendation, prediction, treatment, and patient preferences remain distinct decisions.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  4. No.19

    Monthly_special

    The Implantation Honeymoon—Who Gets the Credit: Implant, Stimulation, or Time?

    When seizures change after intracranial electrodes are implanted but before stimulation begins, who gets the credit: the implant, the stimulation, or time itself?

    In this discussion · 6 topics

    1. Some adults reported fewer seizures after SEEG electrode insertion, but the study design cannot show that implantation caused the improvement.
    2. During intracranial monitoring, implantation was linked to a modest delay before the first seizure—not a clear reduction in daily seizure frequency.
    3. RNS brain recordings can keep changing for months after surgery, but an evolving electrical signal does not by itself mean seizures are improving.
    4. Rare RNS and DBS cases show that improvement can begin before stimulation, while medication changes, recovery, and natural seizure variability remain possible explanations.
    5. A single-center abstract from AED editor Erafat Rehim's group suggests early postimplant change may predict later RNS response, but the finding remains unvalidated.
    6. In the sham-controlled NAUTILUS trial, active stimulation did not meet the prespecified effectiveness endpoint; later supportive analyses do not replace that primary result.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  5. No.18

    Monthly_special

    How Safe Is Safe? The Long-Term Tradeoffs of Common Anti-Seizure Medications.

    When a patient asks, “You say Keppra is safe long term. Exactly how safe is it?”, the honest answer is not one lifetime percentage.

    In this discussion · 6 topics

    1. Long-term safety is a changing clinical profile, not one lifetime percentage.
    2. Approval history and structured follow-up are different evidence clocks.
    3. Long-duration extension studies describe selected continuers and cannot guarantee safety for every starter.
    4. Levetiracetam's main ongoing burdens are behavioral or fatigue-related tolerability and changing renal exposure rather than a recognized progressive organ-toxicity syndrome.
    5. Lamotrigine combines a front-loaded serious-rash risk with an enriched long-term continuation literature.
    6. Lacosamide combines neurologic tolerability with cardiac-conduction susceptibility that changes with comorbidity and interacting drugs.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  6. No.17

    Weekly_recent_studies

    What Counts as Neuromodulation Success?

    Should the 50% responder rate remain the primary definition of neuromodulation success?

    In this discussion · 6 topics

    1. Keep the 50% responder rate as a standardized anchor, but never let it stand alone.
    2. Pair a threshold with the continuous reduction distribution, seizure freedom, denominator, and time horizon.
    3. Similar outcomes at 12 months do not prove similar early experience or device superiority.
    4. Quality of life, harms, and treatment burden are core counseling domains.
    5. A positive secondary electrographic signal does not erase a negative prespecified diary primary result.
    6. Small internally held-out biomarker results and post-treatment associations remain hypothesis-generating.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  7. No.16

    Weekly_recent_studies

    Signals, Silence, and Zero Events.

    What can an observational association, the absence of a consistent reported pattern, and zero observed events actually justify in medication counseling? Episode 16 compares a nationwide prenatal antiseizure-medication cohort, an eslicarbazepine pregnancy safety database, and a selected cenobamate restart cohort to show why every safety conclusion must be matched to the data-generating system behind it.

    In this discussion · 5 topics

    1. An adjusted prenatal-exposure association is not a causal medication effect.
    2. A spontaneous-report database can reveal repeated patterns but cannot estimate incidence without a valid denominator and comparator.
    3. No consistent reported eslicarbazepine pattern is not proof of pregnancy safety.
    4. Zero attributed events in 32 selected restart patients narrows uncertainty but does not make the risk zero; the approximate rule-of-three upper bound is near 9%.
    5. Residual exposure remains a pharmacokinetic hypothesis, and the cohort does not authorize universal maintenance-dose restart advice.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  8. No.15

    Monthly_special_fellow_bootcamp

    Fellow Bootcamp: OSA Is Not Just a Comorbidity.

    When should obstructive sleep apnea be treated as more than a passive comorbidity in epilepsy care? This Fellow Bootcamp special uses the nine Bradford Hill viewpoints to examine evidence on co-occurrence, seizure and interictal-discharge burden, incident and late-onset epilepsy, SUDEP-risk markers, and the limits of current CPAP data.

    In this discussion · 5 topics

    1. Bradford Hill viewpoints organize causal reasoning; they are not a checklist, vote, or proof score.
    2. OSA is commonly reported in people with epilepsy, but prevalence evidence remains heterogeneous.
    3. Incident and late-onset epilepsy findings support a hypothesis rather than proof and remain vulnerable to residual confounding and exposure misclassification.
    4. Revised SUDEP risk scores are surrogate markers, not observed SUDEP events.
    5. Treat confirmed OSA for established sleep-medicine indications and track epilepsy outcomes without promising seizure or prevention benefit.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  9. No.14

    Monthly_special_fellow_bootcamp

    Fellow Bootcamp: From EMU to SEEG to Surgery.

    How should an epilepsy fellow turn EMU findings, imaging, neuropsychology, and other phase 1 data into a defensible surgical hypothesis? This Fellow Bootcamp special reviews the cortical zones used in presurgical reasoning, when SEEG may resolve an actionable uncertainty, the limits of sparse intracranial sampling, and how teams orient among resection, ablation, disconnection, neuromodulation, or no procedure.

    In this discussion · 5 topics

    1. Phase 1 evaluation should build a coherent electroclinical hypothesis and expose meaningful contradictions.
    2. Symptomatogenic, irritative, seizure-onset, epileptogenic-lesion, functional-deficit, eloquent-cortex, and epileptogenic zones may overlap but are not interchangeable.
    3. A visible lesion can strengthen a hypothesis but does not independently establish causality.
    4. S-E-E-G is spatially limited sampling and is most useful when it tests bounded alternatives that could change treatment.
    5. Treatment choice integrates targetability, network distribution, functional risk, expected benefit, residual uncertainty, and patient goals.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  10. No.13

    Monthly_special

    Temporal Encephaloceles: Lesion, Network, and How Much to Resect?

    This monthly special debate asks how epilepsy surgery teams should reason about temporal encephaloceles: as a leading surgical target, as a clue to broader temporal network involvement, or both.

    In this discussion · 5 topics

    1. Temporal encephaloceles can be missed on routine review and may require deliberate skull-base re-review or additional imaging.
    2. Finding a temporal encephalocele is not the same as proving seizure onset from the herniated tissue.
    3. Concordant imaging, semiology, EEG, PET, neuropsychology, and invasive recordings can support a lesion-centered hypothesis in selected cases.
    4. Surgical extent should follow the full presurgical picture, not a default rule for or against hippocampectomy.
    5. The evidence base is mainly retrospective and selected, so the episode frames conference reasoning rather than a guideline.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  11. No.12

    Weekly

    Care Pathways Shape Epilepsy Outcomes.

    This weekly recent-studies episode asks what happens when epilepsy outcomes are shaped not only by medications, procedures, or devices, but by the care pathway around the patient.

    In this discussion · 5 topics

    1. Care pathways are measurable parts of epilepsy care, not just background logistics.
    2. Rural-urban inpatient differences, vEEG access, transition care, and tumor-epilepsy coordination all point to pathway-level gaps.
    3. The studies are mostly observational or service-mapping work, so they support careful questions rather than practice-changing mandates.
    4. Technology can support redesign, but the roadmap source is not proof that specific digital tools improve outcomes.
    5. Repeated ED visits, transition handoffs, and multidisciplinary tumor care are moments to ask whether the patient reached the right diagnostic and longitudinal services.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  12. No.11

    Weekly

    Signals Before Practice Change: GLP-1 Drugs and the Temptation to Overread.

    This weekly recent-studies episode asks how epileptologists should talk about exciting signals before they become practice-changing evidence.

    In this discussion · 5 topics

    1. GLP-1 studies point toward favorable seizure-related associations, but they remain bounded by observational designs, adverse-event coding, EHR outcomes, and residual confounding.
    2. AbuAlrob et al. reported HR 0.82 for EHR-coded seizure recurrence; public framing should treat this as an estimated 18% lower hazard with about a 2.1 percentage-point absolute recurrence difference.
    3. Pediatric levetiracetam remains useful, but the active-comparator evidence does not support an automatic superiority claim.
    4. VNS prognostic factors and the Crutcher cohort are useful research signals, not deterministic bedside selection rules.
    5. The clinical language matters: calling a hypothesis-generating association a breakthrough can reshape patient expectations before the evidence is ready.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  13. No.10

    Monthly_special

    A Positive Signal With a Negative Primary Endpoint: The NAUTILUS Trial.

    This monthly special is a journal-club reading of NAUTILUS, the randomized sham-controlled trial of responsive centromedian thalamic stimulation for drug-resistant idiopathic generalized epilepsy with recurrent generalized tonic-clonic seizures.

    In this discussion · 5 topics

    1. NAUTILUS is an encouraging signal, not a simple positive trial.
    2. The prespecified primary effectiveness endpoint was not statistically significant.
    3. Post hoc and 18-month seizure outcomes matter clinically but cannot erase the endpoint hierarchy.
    4. Centromedian thalamic RNS belongs in careful counseling and referral discussions for selected drug-resistant IGE patients with recurrent GTCS.
    5. The trial does not establish thalamic RNS as standard-of-care therapy for IGE.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  14. No.09

    Monthly_special

    From Paper to Podcast: The AED Assembly Line.

    This special episode explains how Audio Epilepsy Digest is made. Instead of reviewing new epilepsy papers, it follows the AED assembly line from source selection and episode framing through AI-assisted drafting, transcript review, human editorial judgment, public source-review pages, and listener feedback.

    In this discussion · Source packet

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  15. No.08

    Weekly

    Status Epilepticus in Critical Care.

    This weekly recent-studies episode uses papers from roughly the last month, plus ESETT as a landmark context study, to ask what happens when status epilepticus moves beyond the emergency algorithm and becomes a critical-care problem.

    In this discussion · 5 topics

    1. ESETT anchors one second-line convulsive status decision point, but it does not settle ICU/SRSE/NORSE salvage care.
    2. ICU status epilepticus care is shaped by systems constraints, especially cEEG access, training, and workflow.
    3. Point-of-care AI seizure-burden estimates are associated with discharge outcomes, but do not prove that AI-guided treatment improves outcomes.
    4. Perfusion imaging can add diagnostic context in selected seizure-vs-stroke-mimic or IIC situations, but EEG remains central.
    5. VNS and emergency resection are salvage conversations, not routine generalized pathways.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  16. No.07

    Weekly

    Real-World Evidence Meets Surgical Assumptions.

    This weekly recent-studies episode uses papers published in roughly the last month to ask how epileptologists should counsel patients with drug-resistant focal epilepsy when new evidence strengthens some assumptions, weakens others, and warns against turning plausible anatomy or AI output into shortcuts.

    In this discussion · 4 topics

    1. RNS postapproval data strengthen confidence in long-term palliative neuromodulation for selected adults with focal epilepsy, but they do not define universal treatment sequencing.
    2. PMG-related epilepsy can be surgically treatable in selected patients, but the visible malformation is not automatically the full epileptogenic zone.
    3. A 2026 validation study found no association between connectivity-defined piriform cortex resection and seizure freedom, arguing against routine targeting while preserving patient-specific network evaluation.
    4. LLMs can organize seizure-semiology information above chance in a benchmark task, but reasoning and citation errors keep them in the decision-support category.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  17. No.06

    Monthly_special

    From Random Seizures to Risk States.

    Episode 6 examines seizure timing, epilepsy chronobiology, and seizure forecasting.

    In this discussion · 4 topics

    1. Seizure timing can reflect circadian, sleep-wake, sleep-drive, and multidien risk rhythms, but that does not mean seizures are reliably predictable in routine care.
    2. Forecasting claims need past-only implementation, meaningful chance models, simple benchmarks, prospective validation, and attention to false alarms and patient burden.
    3. Wearable, diary, and home EEG studies show why the field is plausible, but feasibility and proof of principle are not the same as clinical effectiveness.
    4. Medication-timing models and sleep-drive experiments are useful for hypothesis generation, not patient-specific treatment advice.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  18. No.05

    Weekly

    Cognition Is Becoming Actionable.

    Episode 5 asks whether epilepsy cognition is moving from passive comorbidity to measurable, partly modifiable care target.

    In this discussion · 4 topics

    1. Tai et al. link self-reported sleep duration with executive function and dementia-risk signal in focal epilepsy, but this remains observational and hypothesis-generating.
    2. The IC-CoDE Portal lowers the barrier to reproducible cognitive phenotyping for research cohorts, but it is not a clinical decision tool.
    3. The rehabilitation trial supports improved patient-reported quality of life and anxiety more strongly than objective memory improvement.
    4. Zelano et al. show survival associations by first ASM in dementia plus epilepsy, but registry data cannot causally rank medications.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  19. No.04

    Weekly

    Drug-Resistant Epilepsy in 2026.

    Does the pathway after two failed antiseizure medications still end in surgery?

    In this discussion · 4 topics

    1. Pellinen's cenobamate findings support a single-center association with delayed or deferred surgery in selected patients, not causal proof that cenobamate replaces surgery.
    2. Kerr and McFarlane frame the essential distinction: surgical delay is not the same as surgical obviation.
    3. FRANCE suggests potential benefit for ANT-DBS in a highly refractory VNS-failed cohort, but it did not statistically prove superiority over best medical therapy.
    4. Aiello's ANT spectral biomarkers are promising and hypothesis-generating, but they are not validated responder-prediction or programming rules.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  20. No.03

    Weekly

    Epilepsy Care Beyond the Seizure Count.

    What should epilepsy care measure when seizure counts are not enough?

    In this discussion · 4 topics

    1. Respiratory physiology may become an important risk-signal domain, but the current respiratory-variability study should not be heard as a validated individual SUDEP prediction tool.
    2. At-home EEG self-monitoring appears feasible for selected, supported patients, but it does not replace routine EEG, ambulatory EEG, EMU evaluation, or expert interpretation.
    3. Patient-facing definitions of ictal impairment of consciousness can be understandable, but terminology comprehension is not the same as proof of improved clinical outcomes.
    4. Patient-burden research reinforces that seizure counts miss mood symptoms, fatigue, sleep disruption, productivity effects, and caregiver burden, while the current survey remains selected and descriptive.

    AI source review / Listen on Spotify / Apple Podcasts / Amazon Music

  21. No.02

    Weekly

    What Seizure Counts Miss.

    What changes in epilepsy care when we widen the lens beyond raw seizure counts?

    In this discussion · 4 topics

    1. Pediatric status epilepticus should trigger earlier and more systematic thinking about genetic evaluation, especially in younger children and mixed focal-generalized phenotypes.
    2. The accelerated long-term forgetting signal in newly diagnosed focal epilepsy is task-specific: story memory and verbal recognition look more vulnerable than a blanket all-domain memory model would suggest.
    3. Dose escalation in generalized epilepsy should remain drug-specific rather than assumed to be monotonic across all ASMs, with the strongest practical caution in this cohort applying to lamotrigine doses above the moderate range.
    4. Rescue-medication effectiveness may be better captured by seizure-interval change than by endpoints borrowed from chronic maintenance treatment, but the current SEIVAL paper is best heard as endpoint-development work rather than practice-changing efficacy proof.

    Show notes & references / Listen on Spotify / Apple Podcasts / Amazon Music

  22. No.01

    Special

    Special Episode: Thalamic sEEG, Standard of Care or Research?

    Should thalamic sEEG sampling be standard of care, selectively hypothesis-driven, or research-only?

    In this discussion · 4 topics

    1. The strongest argument for restraint is not that thalamic recordings are never interesting, but that incremental patient-level clinical benefit remains uncertain in many cases and may not justify routine added sampling.
    2. The strongest argument for selective clinical use is that thalamic signals can become decision-relevant when the pre-implant hypothesis already involves network propagation, neuromodulation targeting, or uncertainty that cortical-only sampling may not resolve.
    3. The pro-neuromodulation position is more intervention-oriented than the stricter research-only framing and treats thalamic sampling as part of a therapeutic planning workflow, not only a localization experiment.
    4. Much of the packet is interpretation and expert argument rather than direct comparative outcomes evidence, so this should be heard as a policy and practice debate, not a settled consensus statement.

    Show notes & references / Listen on Spotify / Apple Podcasts / Amazon Music

About the publication

Audio Epilepsy Digest turns recent epilepsy research into a single weekly audio brief for epileptologists, epilepsy fellows, and surgical epilepsy teams. Episodes favor primary and authoritative sources, prefer full-text synthesis over abstract skimming, and stay explicit about the distinction between what a study supports and what it does not.

The show is an evolving collaboration between a human editor and AI co-hosts. Audio may misinterpret or oversimplify source material; the original published articles remain the authoritative reference for clinical decision-making. Corrections and feedback are welcome and directly shape future issues.